Back to search

Peptide record

TPDB19129

Antibacterial Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB19129
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia
standard
No
A 17-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
FKAWRWAWRWKKLAAPS
Physicochemical Analysis
C109H154N30O19
NDCEQGHIMTYV
AW
2188.61
12.43
5
0
10
+5
-4.60
-0.759
46.47
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
22000
1005.20
1
Residue Composition
number
4
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
3
K
0
M
1
F
1
P
1
S
0
T
4
W
0
Y
0
V
Amino Acid Distribution
A: 4 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 3 M: 0 F: 1 P: 1 S: 1 T: 0 W: 4 Y: 0 V: 0
Chemical Descriptors
17
C109H154N30O19
2188.61
12.43
+5
-4.60
-0.759
Evidence Records 7 records
Evidence 1 Activity

Activity

<2% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
<2% Hemolysis | 256 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 2 Activity

Activity

3.9% Killing
Toxicity
256 µg/mL
Cytotoxic
3.9% Killing | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 3 Activity

Activity

LC50
Toxicity
4028 µg/mL
Cytotoxic
LC50 | 4028 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 4 Activity

Activity

80.22% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
80.22% Hemolysis | 256 | µg/mL | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 5 Activity

Activity

0% Killing
Toxicity
16 µg/mL
Cytotoxic
0% Killing | 16 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 6 Activity

Activity

55% Killing
Toxicity
256 µg/mL
Cytotoxic
55% Killing | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021
Evidence 7 Activity

Activity

LC50
Toxicity
140.6 µg/mL
Cytotoxic
LC50 | 140.6 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Fatty acid modified-antimicrobial peptide analogues with potent antimicrobial activity and topical therapeutic efficacy against Staphylococcus hyicus. | Appl Microbiol Biotechnol | 2021